EP Patent

EP4223317A2 — Modulation of complement activity

Assigned to UCB Holdings Inc · Expires 2023-08-09 · 3y expired

What this patent protects

The present invention provides modulators of complement activity. Also provided are methods of utilizing such modulators as therapeutics.

USPTO Abstract

The present invention provides modulators of complement activity. Also provided are methods of utilizing such modulators as therapeutics.

Drugs covered by this patent

zilucoplan-sodium (ZILUCOPLAN SODIUM)

Patent Metadata

Patent number: EP4223317A2
Jurisdiction: EP
Classification: —
Expires: 2023-08-09
Drug substance claim: No
Drug product claim: No
Assignee: UCB Holdings Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.